GERMANTOWN, Md., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell ...
Neuralstem's NSI-189 trial in major depressive disorder receives FDA approval to advance to Phase Ib
ROCKVILLE, Maryland, December, 27, 2011– Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial ...
40 mg dose showed statistically significant improvement on Cogscreen objective cognitive measures of attention and memory Two additional self-rated secondary endpoints (CPFQ and QIDS) showed ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Results from a randomized, double-blind, ...
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to ...
* Neuralstem Inc - study did not meet its primary efficacy endpoint * Neuralstem Inc - 40 mg qd dose was directionally positive on madrs * Both 40 mg QD and 40 MG bid doses of NSI-189 were ...
Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, has reached over 50% enrollment in its phase 2 ...
June 25, 2012 Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patients were dosed in Phase Ib of its ongoing trial to test the safety of NSI-189 in the treatment of major depressive disorder ...
ROCKVILLE, Md., Oct. 17, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has begun dosing the second cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in ...
Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib
ROCKVILLE, Md., Dec. 27, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical ...
ROCKVILLE, Md., Oct. 17, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has begun dosing the second cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results